Pharmaceutical companies Elan and Wyeth have announced that they have been granted a further seven patents in the US on immunotherapy research and development on the prevention and treatment of Alzheimer's Disease.
Six of the patents relate to the companies' active immunisation approaches to the disease while the seventh patent relates to the passive immunisation approach or administering antibodies directly to the patient.
In 2000, Elan and Wyeth formed a research collaboration to prevent and treat Alzheimer's disease.